EPB 002
Alternative Names: EPB-002Latest Information Update: 01 Apr 2021
At a glance
- Originator Elpis Biopharmaceuticals
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Research Bladder cancer; Pancreatic cancer; Solid tumours
Most Recent Events
- 18 Mar 2021 EPB 002 is available for licensing as of 18 Mar 2021. https://elpisbiopharmaceuticals.com/partnering/
- 01 Mar 2021 Early research in Bladder cancer in USA (Parenteral) (Elpis Biopharmaceuticals pipeline, March 2021)
- 01 Mar 2021 Early research in Pancreatic cancer in USA (Parenteral) (Elpis Biopharmaceuticals pipeline, March 2021)